Nightstar Therapeutics (NITE) PT Raised to $36 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Nightstar Reports Positive Proof of Concept Data from Dose Escalation Study in XIRIUS Trial for NSR-RPGR in XLRP Patients
September 22, 2018 11:58 AM EDTNSR-RPGR data presented at EURETINA 2018 Congress demonstrated proof of concept with durable dose-related improvements seen as early as month 1 across multiple microperimetry analyses
Preliminary efficacy signals observed in 3/3 patients in cohort 3 and 2/6 patients in cohorts 4 and 5, including durable improvements in overall macula sensitivity, central 16 macula sensitivity and number of improved macula loci
NSR-RPGR was well-tolerated with no dose limiting toxicities or serious treatment-related adverse events
XIRIUS expansion study planned to initiate in Q4 2018
Detailed results to be presented at R&D day... More
Nightstar Reports Positive Proof of Concept Data from Dose Escalation Study in XIRIUS Trial for NSR-RPGR in XLRP Patients
September 22, 2018 11:57 AM EDTNSR-RPGR data presented at EURETINA 2018 Congress demonstrated proof of concept with durable dose-related improvements seen as early as month 1 across multiple microperimetry analyses
Preliminary efficacy signals observed in 3/3 patients in cohort 3 and 2/6 patients in cohorts 4 and 5, including durable improvements in overall macula sensitivity, central 16 macula sensitivity and number of improved macula loci
NSR-RPGR was well-tolerated with no dose limiting toxicities or serious treatment-related adverse events
XIRIUS expansion study planned to initiate in Q4 2018
Detailed results to be presented at R&D day on... More
